OQS
ADVM

Occudo Quantitative Strategies’s Adverum Biotechnologies ADVM Stock Holding History

Occudo Quantitative Strategies’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,943
Closed -$30.9K – 935
2023
Q2 		$30.9K Sell
1,943
-3,313
-63% -$34.8K ﹤0.01% 969
2023
Q1 		$37.7K Sell
5,256
-2,578
-33% -$18.2K ﹤0.01% 855
2022
Q4 		$45.4K Sell
7,834
-174
-2% -$1.32K 0.01% 886
2022
Q3 		$76K Hold
8,008
– – 0.01% 1058
2022
Q2 		$96K Hold
8,008
– – 0.01% 1023
2022
Q1 		$105K Sell
8,008
-4,472
-36% -$65.4K 0.01% 1017
2021
Q4 		$220K Buy
12,480
+2,114
+20% +$42.3K 0.02% 864
2021
Q3 		$225K Buy
10,366
+1,856
+22% +$47.4K 0.03% 824
2021
Q2 		$298K Buy
8,510
+6,620
+350% +$357K 0.05% 595
2021
Q1 		$186K Sell
1,890
-4,344
-70% -$522K 0.04% 637
2020
Q4 		$676K Buy
+6,234
New +$771K 0.21% 140

Other funds holding ADVM

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return

Occudo Quantitative Strategies's ADVM Position: Q3 2023 in Review

Occudo Quantitative Strategies sold out of Adverum Biotechnologies (ADVM) in Q3 2023, closing a stake of 1,943 shares — an estimated $30.9K sold.

Occudo Quantitative Strategies first reported a position in ADVM in Q4 2020 and held it in 11 quarters. The position peaked at $676K in Q4 2020. 59 funds tracked by Wall St. Rank hold ADVM as of Q3 2023.

  • Occudo Quantitative Strategies reported no remaining Adverum Biotechnologies position as of Q3 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 1,943 Adverum Biotechnologies shares in Q3 2023, an estimated $30.9K.
  • Occudo Quantitative Strategies first reported a position in Adverum Biotechnologies in Q4 2020 and held it in 11 quarters.
  • Occudo Quantitative Strategies's Adverum Biotechnologies position peaked at $676K in Q4 2020.
  • 59 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.